ALBERTO PARRA
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology ARLINGTON, TX NPI 1376836718
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology TX EMD Serono, Inc. All categories
General Payments — all program years on this page
$28,568.59
- Category: General Payments
- Program years: PY2018–2024
- Record count: 432
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $18,599.95 across 109 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $15,510.00 | 3 |
| Food and Beverage | $3,089.95 | 106 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| EMD Serono, Inc. | $15,681.55 | 7 |
| Janssen Biotech, Inc. | $574.31 | 13 |
| Merck Sharp & Dohme Corporation | $253.88 | 9 |
| Acerta Pharma LLC | $203.25 | 5 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $188.80 | 8 |
| Gilead Sciences, Inc. | $185.96 | 5 |
| Daiichi Sankyo Inc. | $179.89 | 14 |
| PFIZER INC. | $154.29 | 8 |
| Johnson & Johnson Health Care Systems Inc. | $140.63 | 1 |
| Blueprint Medicines Corporation | $139.76 | 2 |
| Regeneron Healthcare Solutions, Inc. | $134.09 | 3 |
| ABBVIE INC. | $93.51 | 4 |
| Astellas Pharma US Inc | $91.84 | 4 |
| Incyte Corporation | $70.86 | 3 |
| EISAI INC. | $67.73 | 3 |
| E.R. Squibb & Sons, L.L.C. | $65.96 | 3 |
| Celgene Corporation | $65.39 | 3 |
| Genmab U.S., Inc. | $51.18 | 2 |
| ARRAY BIOPHARMA INC | $43.67 | 2 |
| Dendreon Pharmaceuticals LLC | $30.62 | 1 |
| SERVIER PHARMACEUTICALS LLC | $24.90 | 1 |
| Tempus AI, Inc | $24.25 | 1 |
| GlaxoSmithKline, LLC. | $22.97 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.82 | 1 |
| Stemline Therapeutics Inc. | $19.62 | 1 |
| Kite Pharma, Inc. | $18.60 | 1 |
| SOBI, INC | $18.37 | 1 |
| AVEO Pharmaceuticals, Inc. | $16.65 | 1 |
| Immunocore Limited | $15.60 | 1 |
By program year
Records — PY2024 (109)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.